Gufic BioSciences Ltd

Gufic BioSciences Dividend

Gufic Biosciences recommended a final dividend of Re. 0.10 per equity share for financial year 2025-26. The distribution is subject to shareholder approval at the upcoming AGM.

Gufic BioSciences Financial Results

Gufic Biosciences reported consolidated total income of ₹946.66 Crore for FY26. The board also recommended a final dividend of ₹0.10 per equity share.

Value

₹946.7 Cr

Gufic BioSciences Q4 FY26 Results: Net Profit ₹21.9 Cr, Up 184.4% YoY

Gufic BioSciences Ltd reported revenue from operations of ₹251.8 Cr (+22.8% YoY) and net profit of ₹21.9 Cr (+184.4% YoY) for Q4 FY26.

Key figure

Net profit ₹21.9 Cr · +184.4% YoY

Gufic BioSciences Financial Results

Gufic Biosciences reported audited FY26 results and recommended a 10% final dividend. The Board also approved a ₹5.75 Crore equity investment in Saraswat Co-operative Bank.

Value

₹0.58 Cr

Gufic BioSciences Other Announcement

Gufic Biosciences submitted its Annual Secretarial Compliance Report for the financial year 2026. The report confirms overall regulatory compliance with noted historical fine payments.

Gufic BioSciences Board Meeting Date

Gufic Biosciences scheduled a May 29 board meeting to approve FY2026 audited results and consider a final dividend. Trading remains closed until 48 hours post-declaration.

Gufic BioSciences Acquisition Worth ₹0.47 Cr

Gufic Biosciences Limited has completed a further investment of ₹0.47 Crore (USD 50,000) in Selvax Pty Ltd. The transaction involved subscribing to 378,350 ordinary shares at AUD 20 cents per share. This strategic investment strengthens Gufic's international portfolio and was finalized on April 28, 2026.

Value

₹0.47 Cr

Gufic BioSciences Acquisition Worth ₹0.47 Cr

Gufic Biosciences Limited invested USD 50,000 (₹0.47 Crore) to acquire 3,78,350 additional shares in Australian biotech firm Selvax Pty Ltd. This strategic move aims to develop novel immunotherapy treatments for solid tumours. Following this transaction, Gufic's total holding in Selvax reached 16,85,350 shares, strengthening its oncology and biotechnology portfolio.

Value

₹0.47 Cr

Gufic BioSciences Other Announcement

Gufic Biosciences Limited submitted its quarterly compliance certificate for the period ended March 31, 2026. Issued by MUFG Intime India, the certificate confirms that securities received for dematerialisation were processed and listed on the stock exchanges. No shareholder requests were received during the quarter.

Gufic BioSciences Legal & Regulatory

Gufic Biosciences received an income tax order reducing a prior demand to Rs. 11.76 Lakhs, but imposing a penalty of Rs. 23.52 Lakhs (0.24 Cr) for under-reported income. The company intends to appeal the decision before the Commissioner of Income Tax (Appeals) based on tax consultant advice.

Value

₹0.24 Cr